358 related articles for article (PubMed ID: 18492751)
21. Primary Squamous Cell Carcinoma of the Thyroid Has a Molecular Genetic Profile Distinct From That of Anaplastic Thyroid Carcinoma: A Whole Exome Sequencing and Gene Expression Profiling Study.
Ye M; Guo Z; Xu J; Jin Y; He X; Ge M
Am J Surg Pathol; 2024 May; ():. PubMed ID: 38775423
[TBL] [Abstract][Full Text] [Related]
22. Lysicamine Reduces Protein Kinase B (AKT) Activation and Promotes Necrosis in Anaplastic Thyroid Cancer.
Rodrigues MT; Michelli APP; Caso GF; de Oliveira PR; Rodrigues-Junior DM; Morale MG; Machado Júnior J; Bortoluci KR; Tamura RE; da Silva TRC; Raminelli C; Chau E; Godin B; Calil-Silveira J; Rubio IGS
Pharmaceuticals (Basel); 2023 Dec; 16(12):. PubMed ID: 38139812
[TBL] [Abstract][Full Text] [Related]
23. Genetic code expansion, click chemistry, and light-activated PI3K reveal details of membrane protein trafficking downstream of receptor tyrosine kinases.
Koh DS; Stratiievska A; Jana S; Otto SC; Swanson TM; Nhim A; Carlson S; Raza M; Naves LA; Senning EN; Mehl R; Gordon SE
bioRxiv; 2024 May; ():. PubMed ID: 37693391
[TBL] [Abstract][Full Text] [Related]
24. Control of gastruloid patterning and morphogenesis by the Erk and Akt signaling pathways.
Underhill EJ; Toettcher JE
Development; 2023 Aug; 150(16):. PubMed ID: 37590131
[TBL] [Abstract][Full Text] [Related]
25. Molecular pathways in periampullary cancer: An overview.
Apurva ; Abdul Sattar RS; Ali A; Nimisha ; Kumar Sharma A; Kumar A; Santoshi S; Saluja SS
Cell Signal; 2022 Dec; 100():110461. PubMed ID: 36096460
[TBL] [Abstract][Full Text] [Related]
26. Venus kinase receptors: prospects in signaling and biological functions of these invertebrate kinases.
Dissous C; Morel M; Vanderstraete M
Front Endocrinol (Lausanne); 2014; 5():72. PubMed ID: 24860549
[TBL] [Abstract][Full Text] [Related]
27. Multi-Platform Classification of IDH-Wild-Type Glioblastoma Based on ERK/MAPK Pathway: Diagnostic, Prognostic and Therapeutic Implications.
Georgescu MM
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572759
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathogenesis and mechanisms of thyroid cancer.
Xing M
Nat Rev Cancer; 2013 Mar; 13(3):184-99. PubMed ID: 23429735
[TBL] [Abstract][Full Text] [Related]
29. Integrated genomic characterization of papillary thyroid carcinoma.
Cancer Genome Atlas Research Network
Cell; 2014 Oct; 159(3):676-90. PubMed ID: 25417114
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
Kunstman JW; Juhlin CC; Goh G; Brown TC; Stenman A; Healy JM; Rubinstein JC; Choi M; Kiss N; Nelson-Williams C; Mane S; Rimm DL; Prasad ML; Höög A; Zedenius J; Larsson C; Korah R; Lifton RP; Carling T
Hum Mol Genet; 2015 Apr; 24(8):2318-29. PubMed ID: 25576899
[TBL] [Abstract][Full Text] [Related]
31. Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis?
Melo M; da Rocha AG; Vinagre J; Sobrinho-Simões M; Soares P
J Clin Oncol; 2015 Feb; 33(6):667-8. PubMed ID: 25605839
[No Abstract] [Full Text] [Related]
32. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
33. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
[TBL] [Abstract][Full Text] [Related]
34. IQGAP1 plays an important role in the invasiveness of thyroid cancer.
Liu Z; Liu D; Bojdani E; El-Naggar AK; Vasko V; Xing M
Clin Cancer Res; 2010 Dec; 16(24):6009-18. PubMed ID: 20959410
[TBL] [Abstract][Full Text] [Related]
35. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
36. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Tirrò E; Martorana F; Romano C; Vitale SR; Motta G; Di Gregorio S; Massimino M; Pennisi MS; Stella S; Puma A; Gianì F; Russo M; Manzella L; Vigneri P
Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31540307
[TBL] [Abstract][Full Text] [Related]
37. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Landa I; Ibrahimpasic T; Boucai L; Sinha R; Knauf JA; Shah RH; Dogan S; Ricarte-Filho JC; Krishnamoorthy GP; Xu B; Schultz N; Berger MF; Sander C; Taylor BS; Ghossein R; Ganly I; Fagin JA
J Clin Invest; 2016 Mar; 126(3):1052-66. PubMed ID: 26878173
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C; Ciampi R; Elisei R
Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
[TBL] [Abstract][Full Text] [Related]
39. Molecular genetics and diagnosis of thyroid cancer.
Nikiforov YE; Nikiforova MN
Nat Rev Endocrinol; 2011 Aug; 7(10):569-80. PubMed ID: 21878896
[TBL] [Abstract][Full Text] [Related]
40. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Lim H; Devesa SS; Sosa JA; Check D; Kitahara CM
JAMA; 2017 Apr; 317(13):1338-1348. PubMed ID: 28362912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
